Status:
RECRUITING
Evaluating the Impact of Different Methods of HPV DNA Testing for Cervical Cancer Screening in Primary Care Settings
Lead Sponsor:
National Healthcare Group Polyclinics
Collaborating Sponsors:
National Healthcare Group, Singapore
KK Women's and Children's Hospital
Conditions:
Uterine Cervical Neoplasms
Eligibility:
FEMALE
30-69 years
Phase:
NA
Brief Summary
Primary objective of the study is to determine the extent that offering of self-sampling in addition to clinician-sampling Human Papillomavirus (HPV) DNA testing will increase detection of HPV DNA thr...
Detailed Description
This study is a pragmatic, multi-center, 1:1 randomized controlled trial designed to evaluate the impact of self-sampling HPV DNA testing on clinical outcomes and cost-effectiveness in cervical cancer...
Eligibility Criteria
Inclusion
- 30-69 years old female Singapore citizens
- Due for cervical cancer screening
- Engaged in sexual intercourse before
- Able to give informed consent
- Able to read and communicate in English, Chinese or Malay
Exclusion
- Virgo intacta
- Pregnancy
- History of cervical cancer, precancerous cervical lesions and total hysterectomy
Key Trial Info
Start Date :
August 5 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT06528184
Start Date
August 5 2024
End Date
December 1 2026
Last Update
February 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Healthcare Group Polyclinics
Singapore, Singapore, Singapore, 138543